PMN (promisneurosciences.com) יתרות המזומנים של החברה

ProMIS Neurosciences (PMN) maintains a high reputation for developing precision therapies for neurodegeneration targeting harmful brain proteins. The cash balance history demonstrates the business's liquidity, while the 0.04 metric reflects current dynamics. Intellectual capital regarding Alzheimer's disease treatment paves the way for licensing agreements, although the absence of commercial sales temporarily precludes pricing power.
פילוחים אנליטיים ודוחות נתונים של חברת ProMIS Neurosciences, Inc. (PMN)

This indicator measures the volume of liquid assets, determining the business's ability to maintain operational activities and weather market downturns without external borrowing. By analyzing the amount of cash resources, an investor assesses the company's resilience to interest rate changes, which is critical for ProMIS Neurosciences (PMN) during a period of costly antibody clinical trials, where controlling the burn rate of R&D capital directly impacts the issuer's survival.